iQure Pharma
Business Services · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
475 Wall St, Princeton, New Jersey, 0854...Website
www.iqurepharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About iQure Pharma
iQure Pharma is a clinical-stage biotech company focused on developing innovative therapies for central nervous system (CNS) disorders by restoring glutamate homeostasis. Their lead product, iQ-007, is a first-in-class small molecule currently in Phase 1 clinical trials for treatment-resistant epilepsy, aimed at enhancing the function of the main glutamate transporter to prevent neuronal damage. The company's research targets excitotoxicity, a mechanism implicated in various CNS conditions, including neurodegeneration and pain. iQure Pharma collaborates with prestigious institutions to validate its scientific approach and expand its therapeutic pipeline.Explore more
iQure Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is iQure Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at iQure Pharma
Funding: Get notified immidiatlly once iQure Pharma has new funding data
Earning: See what the market has to say on iQure Pharma recently announced quarterly report
iQure Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if iQure Pharma had a recent Job posting/layoffs
Check if iQure Pharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if iQure Pharma is spiking on competitors!
Product Launch: Get notified when iQure Pharma launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at iQure Pharma
Find 2 more new buyers
Compare Similar Companies to iQure Pharma
Compare insights from companies similar to iQure Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
iQure Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
iQure Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about iQure Pharma.
iQure Pharma financials insights
Gather financial insights about iQure Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$600K
2023
Other Financing Round
$1.2M
2026
Private Equity
$650K
iQure Pharma Tech Stack
A closer look at the technologies used by iQure Pharma
iQure Pharma News & Media
iQure Pharma Secures US Patent for iQ-007, a First-in-Class Small Molecule Restoring Glutamate Balance in CNS Disorders
PRINCETON, N.J., Sept. 29, 2025 /PRNewswire/ -- iQure Pharma, a clinical-stage biotech company breaking the cycle of excitotoxicity by restoring glutamate balance to treat CNS disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a US patent for...iQure Pharma Appoints Former UCB Chief Medical Officer and Head of Development, Prof. Iris Loew-Friedrich, MD, as Clinical and R&D Advisor
PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- iQure Pharma, a clinical-stage biotech company breaking the cycle of excitotoxicity by restoring glutamate balance to treat CNS disorders, today announced the appointment of Prof. Dr. Iris Loew-Friedrich as Clinical and R&D Advisor. Iris...iQure Pharma Secures Funding from Ventura BioMed Investors and OKG Capital | BioSpace
iQure Pharma Inc. (iQure), a CNS company dedicated to the development of new epilepsy and pain management therapeutics, has completed the first closing of its latest round of funding.Neuropathic Pain Therapeutics Market Report (2022 to 2030) – Iqure Pharma, Abbvie, Bayer AG, Novartis AG, Pfizer Inc.
Pune, Jan. 11, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, “Neuropathic Pain Therapeutics Market By Drug Class (Antidepressants, Anticonvulsants, Local Anesthesia, Opioids, and Steroids), By Application (Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-induced Peripheral Neuropathy, Trigeminal Neuralgia, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) - Global Outlook & Forecast 2022-2030" published by Growth Plus Reports, th
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding iQure Pharma
Sign Up For FreeTo access detailed company insights
iQure Pharma is a clinical-stage biotech company focused on developing innovative therapies for central nervous system (CNS) disorders by restoring glutamate homeostasis. Their lead product, iQ-007, is a first-in-class small molecule currently in Phase 1 clinical trials for treatment-resistant epilepsy, aimed at enhancing the function of the main g... Read More
